YARDLEY, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On November 10, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to seven new employees who recently joined the Company. The inducement awards consist of options to purchase 20,500 shares of the Company’s common stock, restricted stock units (RSUs)

BURLINGTON, Mass., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the Stephens Annual Investment Conference at 4:30 p.m. ET (3:30 p.m. CT) on Wednesday, November 18, 2026. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: . About Vericel Corporation Vericel is a leading

FDA lifted clinical hold on ARD-101 for the treatment of hyperphagia in Prader-Willi Syndrome (PWS) Meeting with the FDA scheduled for the first quarter of 2027 to discuss the Company’s proposed clinical development plan for ARD-101; Company expects to resume PWS clinical activities in 2027 Exploratory data from the terminated HERO and OLE trials showed numerically greater HQ-CT score reductions with ARD-101 than placebo, with a generally well-tolerated safety profile $60.3 million in cash, cash

A single dose of ZL-1503, across dose levels from 200 to 1,000 mg, produced near-complete (≥90%) inhibition of IL-13-stimulated pSTAT6 in healthy volunteers for at least 3 months Extended serum half-life of approximately 40 to 50 days, with dose-proportional exposure, supports the potential for less frequent maintenance dosing ZL-1503 was well tolerated across all doses, with no serious adverse events or anti-drug antibodies detected Data from the Part B trial cohort evaluating multiple ascendin

NorthX Biologics and Mendus are expanding their cell therapy manufacturing collaboration to establish production of donor-derived memory natural killer (NK) cells using Mendus’ proprietary DCOne technology. The initiative is supported by a SEK 977,300 grant (approximately $100,000) from Vinnova, Sweden’s government innovation agency, and builds on the companies’ existing large-scale manufacturing collaboration for Mendus’ lead product candidate, vididencel. The project will focus on producing me

Vadym Ilchenko /Getty Images Windward Bio’s public debut brings this year’s total IPO count well above the sluggish total of eight in 2025. Windward Bio is circling up $175 million in initial public offering funds, money that will push its lead program forward in asthma and another chronic lung disease. The antibody-focused biotech’s expected gross proceeds account for nearly 10.3 million shares sold at $17 per share, according to a Thursday night release . The Swiss startup—which debuted on th

Neurosterix will advance its three-strong range of neuropsychiatric therapies with this financing. Credit: Make more Aerials / Shutterstock.com. Swiss biotech company Neurosterix has banked $105m in a Series B funding round to push its range of neuropsychiatric candidates further down the pipeline. The financing, which was led by RTW Investments and contributed to by Janus Henderson Investors, GV and Acorn Bioventures – among others – will see Neurosterix progress its range of selective alloster

First patient dosed in the Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center, moving SIL204 into active patient treatment New translational data expanded SIL204’s profile, including a coordinated immune-sensitization signature across four KRAS mutations and a native lipoprotein-mediated uptake mechanism that supports systemic administration Third quarter financings increased cash and cash equivalents to $4.8 million and shareholders’ equ

Presented positive updated efficacy and pooled safety data on amsoki-cel in advanced melanoma at the 41st Annual SITC Meeting, including a 67% ORR (n=10/15), median PFS of 8.3 months and median DOR not yet reached at 14.3 months median study follow-up Enrollment is ongoing in registration-enabling cohort of the Phase 1/2 Agni-01 multicenter study, with topline data expected by year-end 2027 Strengthened Board of Directors with appointment of Mark Reisenauer Cash, cash equivalents, and marketable

DENVER, Nov. 13, 2026 (GLOBE NEWSWIRE) -- ( 247MarketNews ) — NeOnc Technologies Holdings (NASDAQ: NTHI) reaches an important clinical-development milestone today as it presents updated findings from two investigational brain cancer programs at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO) in Philadelphia. The presentations put the company's intranasal NEO100 and oral NEO212 programs in focus, with additional clinical evidence arriving as NeOnc prepares for important FDA disc